Canaccord’s John Newman sees 24% upside potential for BLUE shares.
Morgan Stanley’s Joseph Moore notes that though his colleague points to dipping NAND flash chip prices threatening ahead, this just marks under a third of MU’s business.
Canaccord’s John Quealy highlights 3 compelling reasons to buy Plug Power.
Roth Capital’s Suji Desilva is thrilled that Himax’s fourth quarter is tracking ahead of his previous expectations.
Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.
Needham’s Laura Martin appraises ROKU as a “pure-play” on OTT TV-viewing gains without the content risk Netflix poses.
Oppenheimer’s Shaul Eyal now sees 17% upside potential for PANW on back of a powerhouse earnings outclass and full-year guidance raise for fiscal 2018.
Roth Capital’s Darren Aftahi is enticed by SHOP’s international opportunity, merchant solutions penetration, and Instagram integration.
GBH Insights’ Daniel Ives sees plenty of “fuel left in the tank for AMZN to hit “unprecedented” gains.
One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
